阿昔莫司联合瑞舒伐他汀治疗糖尿病伴血脂异常的疗效观察
Effectiveness of acipimox combined rosuvastatin in tredating diabetes mellitus with dyslipidemia
张玉 1戴红双 2马永文1
作者信息
- 1. 大庆龙南医院 163453
- 2. 大庆医学高等专科学校 163312
- 折叠
摘要
目的：观察阿昔莫司联合瑞舒伐他汀治疗糖尿病伴血脂异常的疗效。方法2型糖尿病伴血脂异常患者150例，采用随机、双盲的研究方法分为第3组，每组50例，第1组服用瑞舒伐他汀10mg，1次／天，第2组服用阿昔莫司胶囊250mg，3次／天，第3组瑞舒伐他汀、阿昔莫司胶囊联合应用，疗程8周，比较第3组治疗后血脂及有效率的变化。结果第3组总有效率优于第1组（χ2＝12．36，P＜0．005）和第2组（χ2＝11．11，P＜0．005）。与第1组比较，第3组的甘油三酯下降明显，高密度脂蛋白上升明显（ P＜0．001）；与第2组比较，第3组的总胆固醇及低密度脂蛋白胆固醇下降明显（ P＜0．001）。结论阿昔莫司联合瑞舒伐他汀对2型糖尿病伴血脂异常的患者有较好疗效。
Abstract
Objectives To observe the clinical effectiveness of acipimox combined rosuvastatin in tredating diabetes mellitus with dyslipidemia.Methods The 150 patients with dyslipidemia and type 2 diabetes Mellitus were selected and randomly divided into three groups.Each group was 100 cases.The first group received the treatment of rosuvastatin ,the second group received acipimox , and the last group received rosuvastatin combined rosuvastatin .The therapy went on 8 weeks.At the end of the study ,to compare the change of blood-fat and effective rate of the three groups .Results The total effective rate of the third group exceeded that of the first group(χ2 =12.36, P<0.005) and the second group (χ2 =11.11, P<0.005).Compared with the frist group, TG of the third group was significantly decreased,and HDL-C was significantly increased(P<0.001).Compared with the second group, TC and LDL-C of the third group was significantly decreased (P<0.001).Conclusions Treatment of acipimox combined rosuvastatin was efficient on diabetes mellitus with dyslipidemia .
关键词
Acipimox/Rosuvastatin/Diabetes mellitus/dyslipidemiaKey words
Acipimox/Rosuvastatin/Diabetes mellitus/dyslipidemia引用本文复制引用
出版年
2015
国家科技期刊平台
NSTL
维普
万方数据